TIM-3 CAR-CIK

TIM-3 CAR-CIK is an experimental cell therapy consisting of Cytokine-Induced Killer (CIK) cells engineered to express a Chimeric Antigen Receptor (CAR) targeting T-cell Immunoglobulin Mucin-3 (TIM-3). Developed primarily for the treatment of Acute Myeloid Leukemia (AML), this therapy utilizes a third-generation CAR construct comprising CD28 and OX40 costimulatory domains, or a dual-targeting "IF-BETTER" platform pairing a TIM-3 CAR with a CD33-targeting Cytokine-Costimulatory Receptor (CCR). A distinguishing feature of the TIM-3 scFv (derived from the antagonistic antibody clone M6903) is its glycoform-selective binding; the interaction is selectively enhanced by AML-specific hyper-fucosylated and hyper-sialylated N-glycans. This mechanism provides a safety window by preferentially targeting leukemic stem cells (LSCs) and blasts while sparing healthy TIM-3+ immune cells that lack these aberrant glycosylation patterns. The cells are typically engineered using the non-viral Sleeping Beauty transposon system.

Other names

anti-TIM-3 CAR-CIKanti-TIM3 CAR-CIKanti-TIM 3 CAR-CIKTIM-3-directed CAR-CIKTIM3-directed CAR-CIKTIM 3-directed CAR-CIK